Key result
In vitro exposure of whole blood to supratherapeutic concentrations of sugammadex (301 μg/mL) significantly increased reaction time to clot formation compared to control (8.2 vs 5.6 minutes, p<0.0001).
Why the study?
Does exogenous sugammadex reduce coagulation in whole blood from healthy orthopedic surgical patients?
Population
14 healthy patients (aged 19-45 years, ASA physical status 1-2) undergoing elective orthopedic surgery
Comparison
Exogenous sugammadex added to citrated whole… vs Control in citrated whole blood
Design
Preclinical, Observer blinded to the group assignment and sampling time
Authors
Loading...
In vitro TEG changes at high sugammadex doses are hypothesis-generating; should not alter practice pending in vivo confirmation.
Does exogenous sugammadex reduce coagulation in whole blood from healthy orthopedic surgical patients?
Absolute Event Rate: 8.2% vs 5.6%
p-value: p=<0.0001
Supratherapeutic concentrations of sugammadex in vitro are associated with moderate hypocoagulation in whole blood from healthy subjects.
Lee et al. (2018) studied Healthy patients undergoing orthopedic surgery (n=14). Sugammadex vs. Control (0 μg/mL) was evaluated on Reaction time (r) to clot formation on thromboelastography (p=<0.0001). In vitro exposure of whole blood to supratherapeutic concentrations of sugammadex (301 μg/mL) significantly increased reaction time to clot formation compared to control (8.2 vs 5.6 minutes, p<0.0001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: